Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677224 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL77520 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL4111065 | 0.84 | HTT (0.65) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL19023351 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL12425238 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL79421 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL2009867 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL13676896 | 0.83 | GAA (0.59) | SMN1; SMN2NPC1RAB9ACYP2D6CYP3A4 | |
| SCHEMBL19023194 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AHTT | |
| SCHEMBL19022988 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | SMN1; SMN2 4780/4885CYP2C19 1175/4885NPC1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.